[1]
|
Silva, S.N. (2021) Special Issue: Genetic Perspectives in Thyroid Cancer. Genes (Basel), 12, 126.
https://doi.org/10.3390/genes12020126
|
[2]
|
Du, L., Li, R., Ge, M., et al. (2019) Incidence and Mortality of Thy-roid Cancer in China, 2008-2012. Chinese Journal of Cancer Research, 31, 144-151. https://doi.org/10.21147/j.issn.1000-9604.2019.01.09
|
[3]
|
Du, L., Zhao, Z., Zheng, R., et al. (2020) Epidemiology of Thyroid Cancer: Incidence and Mortality in China, 2015. Frontiers in Oncology, 10, Article No. 1702. https://doi.org/10.3389/fonc.2020.01702
|
[4]
|
卢平, 胡婕, 程双华, 等. 甲状腺乳头状癌患者TPO与CD56表达的诊断价值[J]. 诊断病理学杂志, 2020, 27(3): 172-175.
|
[5]
|
Cibas, E.S. and Ali, S.Z. (2017) The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid, 27, 1341-1346. https://doi.org/10.1089/thy.2017.0500
|
[6]
|
Kimura, E.T., Nikiforova, M.N., Zhu, Z., et al. (2003) High Prevalence of BRAF Mutations in Thyroid Cancer: Genetic Evidence for Constitutive Activation of the RET/PTC-RAS-BRAF Sig-naling Pathway in Papillary Thyroid Carcinoma. Cancer Research, 63, 1454-1457.
|
[7]
|
Perdas, E., Stawski, R., Nowak, D., et al. (2018) Potential of Liquid Biopsy in Papillary Thyroid Carcinoma in Context of miRNA, BRAF and p53 Muta-tion. Current Drug Targets, 19, 1721-1729.
https://doi.org/10.2174/1389450119666180226124349
|
[8]
|
侯卫华, 李从洋, 孟祥超, 刘艳锋, 于兵兵, 张萌, 王建业, 段尚林, 胡学信. 免疫组化蛋白标志物在甲状腺乳头状癌组织中的表达[J]. 肿瘤基础与临床, 2018, 31(3): 192-195.
|
[9]
|
Huang, L., Wang, X., Huang, X., et al. (2018) Diagnostic Significance of CK19, Galectin-3, CD56, TPO and Ki67 Expression and BRAF Mutation in Papillary Thyroid Carcinoma. Oncology Letters, 5, 4269-4277.
https://doi.org/10.3892/ol.2018.7873
|
[10]
|
Tastekin, E., Keskin, E., Can, N., et al. (2019) CD56, CD57, HBME1, CK19, Galectin-3 and p63 Immunohistochemical Stains in Differentiating Diagnosis of Thyroid Benign/Malign Lesions and NIFTP. Polish Journal of Pathology, 70, 286-294. https://doi.org/10.5114/pjp.2019.93131
|
[11]
|
王力群, 郑曦, 吴钦穗, 等. BRAF基因在甲状腺癌细针穿刺标本中的表达研究[J]. 中国医药指南, 2018, 16(19): 164-165.
|
[12]
|
Basolo, F., Torregrossa, L., Giannini, R., et al. (2010) Correlation between the BRAF V600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters: Analysis of 1060 Cases. The Journal of Clinical Endocrinology & Metabolism, 95, 4197-4205. https://doi.org/10.1210/jc.2010-0337
|
[13]
|
Kim, S.K., Woo, J.W., Lee, J.H., et al. (2016) Chronic Lymphocytic Thyroiditis and BRAF V600E in Papillary Thyroid Car-cinoma. Endocrine-Related Cancer, 23, 27-34. https://doi.org/10.1530/ERC-15-0408
|
[14]
|
Yan, C., Huang, M., Li, X., et al. (2019) Relationship between BRAF V600E and Clinical Features in Papillary Thyroid Carcinoma. Endocrine Connections, 8, 988-996. https://doi.org/10.1530/EC-19-0246
|
[15]
|
赵慧敏. 甲状腺癌的分子诊断现状研究[J]. 检验医学与临床, 2020, 17(8): 1135-1138.
|
[16]
|
Ceyran, A.B., Senol, S., Simsek, B.Ç., et al. (2015) Role of CD56 and e-Cadherin Expression in the Differential Diagnosis of Papillary Thyroid Carcinoma and Suspected Follicular-Patterned Lesions of the Thyroid: The Prognostic Importance of e-Cadherin. International Journal of Clinical and Experimental Pathology, 8, 3670-3680.
|
[17]
|
冯耀霞, 张岚, 李群锋, 等. 恶性潜能未定的高分化甲状腺肿瘤中CK19、Galectin-3、HBME-1和TPO的表达及意义[J]. 实用肿瘤杂志, 2017, 32(4): 362-366.
|
[18]
|
许军, 丁旭贝, 肖光雄. 甲状腺微小乳头状癌组织中CK19、TPO、Galectin-3和Survivin蛋白表达水平及诊断价值[J]. 解放军医药杂志, 2017, 29(6): 48-50.
|
[19]
|
Liu, Z., Li, X., Shi, L., et al. (2014) Cytokeratin 19, Thyroperoxidase, HBME-1 and Galectin-3 in Evalua-tion of Aggressive Behavior of Papillary Thyroid Carcinoma. International Journal of Clinical and Experimental Medi-cine, 7, 2304-2308.
|
[20]
|
周荣璟, 丁金旺, 赵海菲, 等. 甲状腺良恶性病变中HCK、HBME-1及TPO的表达及临床价值[J]. 浙江医学, 2017, 39(22): 1972-1975.
|